IRL 790

Drug Profile

IRL 790

Alternative Names: IRL790

Latest Information Update: 04 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Integrative Research Laboratories
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 30 Oct 2015 Phase-I clinical trials in Parkinson's disease in Sweden (unspecified route)
  • 30 Oct 2015 Swedish Medical Products Agency (MPA) and the Regional Ethical Review Board, Uppsala, approves initiation of a phase I trial for Parkinson's disease before October 2015
  • 21 Oct 2014 Preclinical trials in Parkinson's disease in Sweden (unspecified route) before October 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top